Audentes commences dosing in Phase I/II trial for myotubular myopathy

US-based biotechnology firm Audentes Therapeutics has commenced patient dosing in the Phase I/II ASPIRO clinical trial of its product candidate AT132 to treat X-linked myotubular myopathy (XLMTM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news